Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29378763 | 1.00 | PGR (0.38) | PGRARKDM4EALDH1A1HPGD | |
| SCHEMBL12594299 | 0.81 | — | — | |
| SCHEMBL4318070 | 0.80 | AXL (0.38) | — | |
| SCHEMBL29431048 | 0.78 | HTR2A (0.35) | — | |
| SCHEMBL2105174 | 0.78 | HTR2A (0.35) | — | |
| SCHEMBL30084290 | 0.78 | — | — | |
| SCHEMBL2111090 | 0.78 | ELANE (0.37) | KDM4EALDH1A1HPGDCLK4CDK2 | |
| SCHEMBL2113207 | 0.78 | — | — | |
| SCHEMBL14722341 | 0.78 | — | — | |
| SCHEMBL1683476 | 0.78 | KDM4E (0.30) | KDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12304910-B2 | Janus kinase (JAK) family inhibitor, preparation of same, and applications thereof | JIANGSU VCARE PHARMATECH CO., LTD. (CN) | 2025-05-20 | — | — | US | disclosed |
| EP-3919494-B1 | JANUS KINASE (JAK) FAMILY INHIBITOR, PREPARATION OF SAME, AND APPLICATIONS THEREOF | JIANGSU VCARE PHARMATECH CO LTD (CN) | 2023-05-24 | — | — | EP | disclosed |
| US-20220177467-A1 | Janus Kinase (JAK) Family Inhibitor, Preparation of Same, and Applications Thereof | JIANGSU VCARE PHARMATECH CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
| CN-111518096-B | Janus kinase JAK family inhibitor and preparation and application thereof | 江苏威凯尔医药科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| EP-3919494-A1 | JANUS KINASE (JAK) FAMILY INHIBITOR, PREPARATION OF SAME, AND APPLICATIONS THEREOF | Jiangsu Vcare Pharmatech Co., Ltd (CN) | 2021-12-08 | — | — | EP | disclosed |
| CN-111518096-A | Janus kinase JAK family inhibitor and preparation and application thereof | 江苏威凯尔医药科技有限公司 | 2020-08-11 | — | — | CN | disclosed |
| WO-2020156271-A1 | JANUS KINASE (JAK) FAMILY INHIBITOR, PREPARATION OF SAME, AND APPLICATIONS THEREOF | 江苏威凯尔医药科技有限公司 | 2020-08-06 | — | — | WO | disclosed |
| US-8163767-B2 | Heterocyclic Janus Kinase 3 inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| CN-102127078-A | Heterocyclic janus kinase 3 inhibitors | ASTELLAS PHARMA INC | 2011-07-20 | — | — | CN | disclosed |
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-10-22 | — | — | US | disclosed |
| WO-2008112695-A2 | PYRAZOLO [3,4-D] PYRIMIDINES AND 1, 2, 5, 6-TETRAAZA- AS- INDACENES AS PROTEIN KINASE INHIBITORS FOR CANCER TREATMENT | IRM LLC (BM) | 2008-09-18 | — | — | WO | disclosed |
| CN-101223168-A | Heterocyclic JANUS kinase 3 inhibitors | ASTELLAS PHARMA INC (JP) | 2008-07-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177467-A1 | Janus Kinase (JAK) Family Inhibitor, Preparation of Same, and Applications Thereof | JAK1, JAK3, JAK2 | PGR 2245/4885AR 3627/4885KDM4E 485/4885 |
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | JAK3, JAK2, JAK1 | PGR 1314/4885AR 2218/4885KDM4E 556/4885 |
| US-12304910-B2 | Janus kinase (JAK) family inhibitor, preparation of same, and applications thereof | JAK1, JAK3, JAK2 | PGR 2245/4885AR 3627/4885KDM4E 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.